Figure 1.
Clinically significant asthma exacerbations in the INNOVATE study Reproduced with permission from Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309–316. Copyright © 2005 Blackwell Publishing.
aAdjusted due to a pre-study imbalance in exacerbation rate.
